Introduction: Fatigue is a common symptom occuring in different neurological diseases. It has an influence on social and proffesional live, and daily living activities of the patients. The aim of the study was to assess frequency of fatigue and its association with depression and anxiety in patients with multiple sclerosis (MS).
Material And Methods: The examined group consisted of 44 patients with MS (mean age: 36.3+/-9.4 years). The control group involved 30 healthy volunteers. All the subjects fulfilled two questionnaires: Fatigue Severity Scale and Hospital Anxiety and Depression Scale.
Results: Fatigue was present in 29 MS patients (66%) and in 8 controls (26.7%) (p=0.0002). Anxiety was noticed in 11 MS patients (25%) and in 2 controls (6.7%) (p=0.002). Depression was diagnosed in 3 MS patients (6.8%) and 2 controls (6.7%) (NS). Frequency of fatigue was similar in women and men, but anxiety and depression were more common in women. There was no correlation between fatigue and age, duration of the disease and EDSS. An association between fatigue and depression, but not anxiety, was observed.
Conclusions: Fatigue is a very common symptom in MS, sometimes associated with depression. It should be considered in every patient with MS, independently from age, sex, disability and duration of the disease.
Download full-text PDF |
Source |
---|
Sci Rep
December 2024
Department of Optometry, College of Applied Medical Sciences, King Saud University, Riyadh, 11451, Saudi Arabia.
Globally, the prevalence of coronary artery disease (CAD) is increasing, accounting for a third of all deaths worldwide including myocardial infarctions (MIs) which represent the most severe clinical manifestation of CAD and are among the most dangerous coronary events. Therefore, this study aims to assess the knowledge of symptoms and risk factors of MIs, as well as attitudes and beliefs regarding MIs and confidence in recognizing CAD symptoms in Riyadh, Saudi Arabia. A cross-sectional study was conducted among individuals living in Riyadh, Saudi Arabia between November 2023 and April 2024 to assess their knowledge and beliefs about CAD and MIs.
View Article and Find Full Text PDFRheumatol Int
December 2024
Division of Rheumatology, Department of Internal Medicine, Sorlandet Hospital, Kristiansand, Norway.
Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function, and poor health status, which can influence sexual activity and enjoyment. To explore whether patients with ax-SpA perceive that their health status effects their sexual activity and to identify predictors of these perceived effects on sexual activity after a 5-year follow-up. Data about demographics, disease, medication, health-related quality of life (HRQOL), and sexual quality of life (SQOL) were collected at the baseline and 5-year follow-up.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
Crit Rev Oncol Hematol
December 2024
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, 45110 Ioannina, Greece; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W12 0BZ London, UK. Electronic address:
Background: To contribute to the refinement of future physical activity (PA) guidelines, which have remained mostly generic until now, we performed an umbrella review of meta-analyses for PA in cancer survivors.
Methods: Medline and Scopus databases were searched in January 2024 for systematic reviews and meta-analyses on the association/effect of any type of PA in every cancer type and for any studied outcome. Statistically significant meta-analyses were categorized into four evidence groups (strong, highly suggestive, suggestive, weak) using pre-established grading criteria.
Expert Opin Drug Saf
December 2024
Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: Isocitrate dehydrogenase (IDH) inhibitors hold promise for IDH-mutated cancer patients and demonstrated favorable clinical efficacy. Nonetheless, a comprehensive understanding of the associated toxicities of IDH inhibitors remains notably lacking.
Research Design And Methods: This pharmacovigilance analysis utilized the FDA Adverse Event Reporting System (FAERS) database to assess notable adverse events (AEs) attributed to IDH inhibitors (enasidenib and ivosidenib) from January 2018 to December 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!